Optic neuropathy
Conditions
Interventions
Experimental group:subtenon administration of nerve growth factor is treated with basic medication, which is administered continuously for 12 weeks
Control group:Basic drug treatment, continuous administration for 12 weeks
Sponsors
Department of Ophthalmology, First Medical Center, PLA General Hospital
Eligibility
Sex/Gender
All
Age
18 Years to 60 Years
Inclusion criteria
Inclusion criteria: (1) Age of subjects: 18 to 60 years old (2) Acute vision loss, with or without eye turning pain; (3) At least two of the following abnormalities were combined: relative afferent pupillary block, visual field defects, visual evoked potential abnormalities, and color vision disorders; (4) Exclude inflammatory, traumatic, compressive and infiltrative, toxic, nutrient metabolism, hereditary optic neuropathy, etc. (5) Agree to the treatment plan of this study and adhere to regular follow-up, and voluntarily sign the informed consent form.
Exclusion criteria
Exclusion criteria: (1) The subject is less than 18 years old or older than 60 years old; (2) Those who have corneal opacity, lens opacity, vitreous hemorrhage and other refractive media opacity that affects visual acuity assessment; Patients with other ophthalmic diseases: diabetic retinopathy lesions, epimacular membrane and other diseases (3) Patients with coagulation disorder; (4) Those with severe heart, liver, and kidney insufficiency and cannot tolerate surgery; (5) Pregnant and lactating women; (6) Other patients judged by the principal investigator to be unsuitable for inclusion in the study;
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Best Corrected Visual Acuity (BCVA); | — |
Secondary
| Measure | Time frame |
|---|---|
| Visual field, visual evoked potentials, RNFL and GCC alterations in OCT; | — |
Countries
China
Contacts
Public ContactBaoke Hou
The First Medical Center of PLA General Hospital
Outcome results
None listed